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(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.) 1st Editorial Decision 14 October 2011
Thank you for submitting your manuscript for consideration by the EMBO Journal. Please let me first apologise for the long delay in getting back to you with a decision: this was due to the very late return of one of the referee's reports. However, your study has now been seen by three referees whose comments are enclosed. As you will see, all three reviewers express significant interest in your work and are supportive of publication -pending satisfactory revision. Their reports are explicit, so I see little need to go into detail here, and I hope that you will be able to address their concerns without too much difficulty.
Given the referees' positive recommendations, I would like to invite you to submit a revised version of the manuscript, addressing the comments of all three reviewers. I should add that it is EMBO Journal policy to allow only a single round of revision, and acceptance of your manuscript will therefore depend on the completeness of your responses in this revised version. When preparing your letter of response to the referees' comments, please bear in mind that this will form part of the Review Process File, and will therefore be available online to the community. For more details on our Transparent Editorial Process, please visit our website: http://www.nature.com/emboj/about/process.html
We generally allow three months as standard revision time. As a matter of policy, competing manuscripts published during this period will not negatively impact on our assessment of the conceptual advance presented by your study. However, we request that you contact the editor as soon as possible upon publication of any related work, to discuss how to proceed. Should you foresee a problem in meeting this three-month deadline, please let us know in advance and we may be able to grant an extension. Also, please feel free to get in touch should you have any questions or comments about the revision.
Thank you for the opportunity to consider your work for publication. I look forward to your revision.
Yours sincerely,
Editor
The EMBO Journal REFEREE REPORTS Referee #1
In this manuscript, by combining biochemical and crystal structural analyses, the authors demonstrated an important mechanism by which E3-ubiquitin ligase Hakai binds its target molecules. The structural data revealed that dimerization of Hakai through the formation of the atypical ZnF produces a novel pTyr-binding domain, which was named the HYB domain. NMR and extensive mutational analyses identified Hakai residues required for pTyr-binding within the binding pocket. Furthermore, using mass spectrometry, the authors identified novel Hakai-binding proteins and characterized their interaction with Hakai. Overall, the presented data are of high quality. Moreover, extensive biochemical analyses convincingly support the structural data. The identification of a novel pTYR domain is a quite intriguing finding; therefore I feel that this paper is suitable for publication in the EMBO Journal, if the following concerns are properly addressed.
(Major points) * The authors clarified that aa106-206 of Hakai makes unique homodimers, which were confirmed by crystal structural analyses, 3D 15N-NOESY spectrums and gel-filtration chromatography. But these experiments were carried out with the aa106-206 peptide. The authors should demonstrate that full length Hakai can also form homodimers as predicted. To this end, they can conduct co-IP using Flag-Hakai and HA-Hakai in 293 cells.
* The authors proposed that phosphotyrosines of DOK1 are the novel target of Hakai. In Fig. 4 , is DOK1 indeed phosphorylated by Src? * In Figure 6 , the authors should demonstrate that the interaction between E-cadherin and ZNF645 is tyrosine-phosphorylation-dependent. Mukherjee and colleagues extend our knowledge of phosphotyrosine-binding domains through studies of the pY-binding domain of Hakai, an E3 ubiquitin ligase. Hakai specifically recognizes a pY motif on E-cadherin, cortactin and other predicted substrates of Src. Using a combination of Xray crystallography, NMR and biochemical approaches, the authors uncover the structure of the phosphotyrosine-binding infrastructure showing that it bind pY as an antiparallel homodimer in a Zn dependent manner. The novel fold created upon Hakai dimerization was termed the HYB (Hakai pY binding) domain. Binding of the HYB domain to the pY motif in Ecadherin is dependent on the N-terminal hydrophobic (P-2 valine) and more generally, the Cterminal flanking (P+2, P+3) acidic residues. Together, these results reveal a novel dimerizationdependent, phosphotyrosine-binding mode of interaction.
Overall, this manuscript is well written and concise, the experiments are well controlled and informative, providing support to the proposed binding model. I recommend this manuscript for publication in EMBO J. with minor revisions addressing the points below.
Points to address
1) The computational docking of pY peptide to the HYP domain is unconvincing as described. In the absence of more experiments that would nail down the precise binding mode of peptide, I recommend deletion of figure 5e and the associated text from the manuscript.
2) Figure Supp 1e is missing proper labels Referee #3
Mukherjee et al. describe the structure of a novel phosphotyrosine binding domain from the E3-ligase Hakai. The structural analysis is absolutely first-rate, revealing a novel dimeric fold at high resolution. Furthermore, extensive functional data indicates a requirement for dimerization for function, and maps the phosphopeptide binding site. The work will be of great interest to the readers of Embo J and should receive a high priority for publication, but I feel that a few key experiments are missing -their inclusion would greatly strengthen the work: 1. The dimer interface is so extensive that one would almost expect a monomer to be unfolded. Thus little doubt that the authors are correct that it is a dimer in solution as well. Nevertheless, it would be good to have an absolute measurement of mass in solution, by light scattering (SEC-MALS) or analytical ultracentrifugation to confirm, as it is possible that the altered elution of their "dimerdisrupting" mutants are due to mis-folding. CD on the mutants is also a good idea. 2. It would be nice to see in vitro measurement of the affinity of phosphopeptide binding, and comparisons among a few different sequences and tyrosine-phosphorylated vs. non-phosphorylated to really nail the phosphotyrosine-binding domain story. 3.The dimeric structure raises the obvious question of the stoichiometry of binding...can the dimer bind two phosphopeptides or just one, as the authors modeling study seems to suggest? I think it is essential to answer this question. 4. some discussion/analysis of the extent of conservation of residues implicated in pTyr binding is in order.
Also, the title would read better as "Structure of a novel phosphotyrosine binding domain in Hakai that targets E-cadherin" We agree with the reviewer on this point. We have therefore performed experiments where FLAGtagged full-length Hakai was immunoprecipitated from 293 cell lysates and the presence of HAtagged full-length Hakai was subsequently analysed. A typical result of these experiments has been included as Figure 2D . * The authors proposed that phosphotyrosines of DOK1 are the novel target of Hakai. In Fig. 4 , is DOK1 indeed phosphorylated by Src? DOK1 has previously been reported to be a Src substrate. In the seminal report by Luo et al. (2008), a specific sequence in DOK1 (as illustrated in Figure 4A ) was identified to be a primary site of Src.
To clarify this point, the additional sentence "One such particular tyrosine residue was found to be a primary phosphorylation site of Src (Luo et al., 2008) ( Figure 4A )." has been added to the Results section. * In Figure 6 , the authors should demonstrate that the interaction between E-cadherin and ZNF645 is tyrosine-phosphorylation-dependent.
We have included a panel in Figure 6B to indicate tyrosine phosphorylation of E-cadherin in the presence of Src. This panel is labelled PY20 using whole cell lysate samples, and the size is labelled as 130 kDa.
(Minor point) In Fig 6a, Hakai's amino acid numbers are not correct.
We would like to thank the reviewer for pointing out the error. The mistake has been corrected and the numbering of Hakai in Figure 6A has been changed. figure 5e and the associated text from the manuscript. We agree with the reviewer and the figure and its associated text have been removed.
2) Figure Supp 1e is missing proper labels
We would like to thank the reviewer for pointing this out and the necessary labels have been added to Supplementary Figure 1E . We agree with the reviewer that these would be excellent experiments to include. Unfortunately, the facilities for both SEC-MALS and analytical ultracentrifugation are currently unavailable to us, and therefore these experiments cannot be carried out. Another set of experiments using dynamic light scattering have instead been performed. We believe that this technique is an acceptable substitute as the experiments provide information on the molecular size, homogeneity and dynamic radius of the protein in solution. This data is presented in Supplementary Figure 3A . We also agree that CD analyses of the mutants should be performed to show that they have not been mis-folded. The CD experiments have been performed and the results are shown in Supplementary Figure 3B .
It would be nice to see in vitro measurement of the affinity of phosphopeptide binding, and comparisons among a few different sequences and tyrosine-phosphorylated vs. non-phosphorylated to really nail the phosphotyrosine-binding domain story.
We agree with the reviewer that it would be ideal to include such data. As such, we have used the peptide derived from amino acids 749 to 761 of E-cadherin for isothermal titration calorimetry (ITC) studies, which provides optimal binding with Hakai (aa 106 -206). The binding affinity results using both Y754 phosphorylated and non-phosphorylated peptides are shown in Figure 3D of the manuscript. A clear difference in binding between phosphorylated and non-phosphorylated peptides is evident and this is reflected in the full-length protein studies.
3.The dimeric structure raises the obvious question of the stoichiometry of binding...can the dimer bind two phosphopeptides or just one, as the authors modeling study seems to suggest? I think it is essential to answer this question.
We think that this is an interesting question and thank the reviewer for raising it. To address it, we have performed ITC experiments (the same ones as in Point 2) and the results indicate that only one E-cadherin phosphopeptide binds the Hakai (aa 106 -206) dimeric structure. The results are shown in Figure 3D .
some discussion/analysis of the extent of conservation of residues implicated in pTyr binding is in order.
A short section addressing the extent of conservation of the residues involved in pTyr binding and its implications has been included in the Discussion section.
Also, the title would read better as "Structure of a novel phosphotyrosine binding domain in Hakai that targets E-cadherin"
We would like to thank the reviewer for the suggestion. The title has been changed as suggested.
